Article ; Online: Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis.
2024 Volume 24, Issue 1, Page(s) 143
Abstract: Background: Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) affect a significant proportion of patients with IPF. There are limited data to inform therapeutic strategies for AE-IPF, despite its high mortality. We discuss the rationale and ... ...
| Abstract | Background: Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) affect a significant proportion of patients with IPF. There are limited data to inform therapeutic strategies for AE-IPF, despite its high mortality. We discuss the rationale and design of STRIVE-IPF, a randomized, multi-center, open-label Phase IIb clinical trial to determine the efficacy of combined therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG), in comparison to treatment as usual (TAU), among patients with acute IPF exacerbations. Methods: The STRIVE-IPF trial will randomize 51 patients among five sites in the United States. The inclusion criteria have been designed to select a study population with AE-IPF, as defined by American Thoracic Society criteria, while excluding patients with an alternative cause for a respiratory decompensation. The primary endpoint of this trial is six-month survival. Secondary endpoints include supplement oxygen requirement and six-minute walk distance which will be assessed immediately prior to treatment and after completion of therapy on day 19, as well as at periodic subsequent visits. Discussion: The experimental AE-IPF therapy proposed in this clinical trial was adapted from treatment regimens used in other antibody-mediated diseases. The regimen is initiated with TPE, which is expected to rapidly reduce circulating autoantibodies, followed by rituximab to reduce B-cells and finally IVIG, which likely has multiple effects, including affecting feedback inhibition of residual B-cells by Fc receptor occupancy. We have reported potential benefits of this experimental therapy for AE-IPF in previous anecdotal reports. This clinical trial has the potential to profoundly affect current paradigms and treatment approaches to patients with AE-IPF. Trial registration: ClinicalTrials.gov identifier: NCT03286556. |
|---|---|
| MeSH term(s) | Humans ; Idiopathic Interstitial Pneumonias/complications ; Idiopathic Pulmonary Fibrosis/drug therapy ; Immunoglobulins, Intravenous/therapeutic use ; Plasma Exchange ; Rituximab/therapeutic use |
| Chemical Substances | Immunoglobulins, Intravenous ; Rituximab (4F4X42SYQ6) |
| Language | English |
| Publishing date | 2024-03-20 |
| Publishing country | England |
| Document type | Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial |
| ZDB-ID | 2059871-3 |
| ISSN | 1471-2466 ; 1471-2466 |
| ISSN (online) | 1471-2466 |
| ISSN | 1471-2466 |
| DOI | 10.1186/s12890-024-02957-3 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.